Canada
· Delayed Price · Currency is CAD Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of CAD 421.62 billion. The enterprise value is 437.78 billion.
| Market Cap | 421.62B |
| Enterprise Value | 437.78B |
Important Dates
The next estimated earnings date is Wednesday, August 6, 2025.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.61% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.18B |
Valuation Ratios
The trailing PE ratio is 19.35 and the forward PE ratio is 17.03.
| PE Ratio | 19.35 |
| Forward PE | 17.03 |
| PS Ratio | 6.68 |
| PB Ratio | 14.61 |
| P/TBV Ratio | 69.43 |
| P/FCF Ratio | 25.58 |
| P/OCF Ratio | 15.43 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.34, with an EV/FCF ratio of 26.56.
| EV / Earnings | 20.09 |
| EV / Sales | 6.90 |
| EV / EBITDA | 13.34 |
| EV / EBIT | 14.24 |
| EV / FCF | 26.56 |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.86.
| Current Ratio | 0.74 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 0.76 |
| Debt / FCF | 1.50 |
| Interest Coverage | 41.95 |
Financial Efficiency
Return on equity (ROE) is 88.12% and return on invested capital (ROIC) is 47.91%.
| Return on Equity (ROE) | 88.12% |
| Return on Assets (ROA) | 23.29% |
| Return on Invested Capital (ROIC) | 47.91% |
| Return on Capital Employed (ROCE) | 58.02% |
| Revenue Per Employee | 815,590 |
| Profits Per Employee | 281,463 |
| Employee Count | 77,349 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.22 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 7.33 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 53.42 |
| Average Volume (20 Days) | 26,263 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novo Nordisk had revenue of CAD 63.13 billion and earned 21.79 billion in profits. Earnings per share was 4.89.
| Revenue | 63.13B |
| Gross Profit | 53.44B |
| Operating Income | 30.58B |
| Pretax Income | 27.55B |
| Net Income | 21.79B |
| EBITDA | 32.34B |
| EBIT | 30.58B |
| Earnings Per Share (EPS) | 4.89 |
Balance Sheet
The company has 8.65 billion in cash and 24.73 billion in debt, giving a net cash position of -16.07 billion.
| Cash & Cash Equivalents | 8.65B |
| Total Debt | 24.73B |
| Net Cash | -16.07B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 28.85B |
| Book Value Per Share | 6.50 |
| Working Capital | -12.85B |
Cash Flow
In the last 12 months, operating cash flow was 27.33 billion and capital expenditures -10.85 billion, giving a free cash flow of 16.48 billion.
| Operating Cash Flow | 27.33B |
| Capital Expenditures | -10.85B |
| Free Cash Flow | 16.48B |
| FCF Per Share | n/a |
Margins
Gross margin is 84.65%, with operating and profit margins of 48.43% and 34.51%.
| Gross Margin | 84.65% |
| Operating Margin | 48.43% |
| Pretax Margin | 43.65% |
| Profit Margin | 34.51% |
| EBITDA Margin | 51.23% |
| EBIT Margin | 48.43% |
| FCF Margin | 26.10% |
Dividends & Yields
Novo Nordisk does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 48.61% |
| Buyback Yield | 0.61% |
| Shareholder Yield | n/a |
| Earnings Yield | 5.17% |
| FCF Yield | 3.91% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Novo Nordisk has an Altman Z-Score of 7.88.
| Altman Z-Score | 7.88 |
| Piotroski F-Score | n/a |